The utility of biomarkers in traumatic brain injury clinical management by unknown
LETTER Open Access
The utility of biomarkers in traumatic brain
injury clinical management
Ana Rodríguez-Rodríguez1 and Juan José Egea-Guerrero2*
See related research by Thelin et al. http://ccforum.biomedcentral.com/articles/10.1186/s13054-016-1450-y
We read the article by Thelin et al. entitled “Utility of
neuron-specific enolase in traumatic brain injury; relations to
S100B levels, outcome, and extracranial injury severity” [1]
with great interest. The authors conclude that while S100B
and neuron-specific enolase (NSE) are both biomarkers for
long-term outcome, S100B is a more accurate predictor.
These findings concur with the results of a previous study
by our research group [2], which showed that serum S100B
levels in severe traumatic brain injury (TBI) patients had a
higher prognostic capacity to predict mortality than NSE.
Similarly, most studies examining the role of diverse bio-
markers in TBI pathology have identified S100B as the
most promising, with the highest prognostic ability to pre-
dict short/long-term mortality [3, 4]. In recent years, re-
searchers have searched for the ideal diagnostic biomarker
that could guide TBI treatment in both primary and
secondary phases. In TBI, the primary injury is caused by
biomechanical damage and the secondary insult is the re-
sult of biochemical cascades triggered by damaged neurons,
glial cells, and blood vessels. The early rise in biomarkers of
secondary injuries could help physicians prevent, or at least
reduce, the extent of this potential damage.
Currently, TBI management is guided by clinical his-
tories and neuroimaging techniques. While these tech-
niques may be advanced, they are more costly than
serum analysis, involve exposure to ionizing radiations,
and have certain limitations when assessing brain dam-
age severity. The ideal biomarker would stratify patients
based on their severity, identifying patients with poorer
prognosis and greater need for treatment before the pa-
tient’s condition worsens. In terms of the nature of the
sample, the ideal biomarker could be detected in serum
or urine (a waste fluid) in order to avoid cerebrospinal
fluid extraction, as reflected in our findings on the role
of urine S100B levels as an early predictor of mortality
after severe TBI [5]. Yet, the variability of potential
inclusion criteria in clinical analysis, and particularly
in clinical trials, hinders the standardization of bio-
marker utility. Studies with such promising results,
like that of Thelin et al. [1], encourage researchers to
continue investigating TBI pathophysiology, to find
the perfect biomarker for TBI assessment, or at least
a set of biomarkers that together can reflect the diverse
injury characteristics of TBI.
Authors’ response
Eric Peter Thelin, Emma Jeppsson, Bo-Michael Bellander and David W. Nelson
Dear Drs. Rodríguez-Rodríguez and Egea-Guerrero
We appreciate that you took the time to read our
recently published article in Critical Care [1].
We agree with the authors concerning the findings in
their recent publication “S100B and neuron-specific eno-
lase as mortality predictors in patients with severe
traumatic brain injury” [2], which unfortunately was not
available to us when we prepared our manuscript. In
addition to mortality, we looked at the different stages of
the Glasgow Outcome Score and noted similar results
where higher serum levels of both S100B and NSE cor-
respond to a more unfavourable outcome.
However, we would also like to stress that further
monitoring (after 72 h) of unconscious TBI patients is of
value, which we showed in a cohort of n = 250 patients
in whom secondary increases of S100B were correlated
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to newly developed radiological findings and subse-
quently a worse outcome [6]. Moreover, these secondary
increases have been shown to aid in clinical decision
making for these patients by other groups [7]. Drs.
Rodríguez-Rodríguez and Egea-Guerrero mention urin-
ary S100B as a potential marker of injury assessment,
and while we appreciate additional compartments could
be sampled, we would like to stress the need for further
research in order to create valid thresholds and temporal
patterns of release for these.
In unison with Drs. Rodríguez-Rodríguez and Egea-
Guerrero, we stress that the field should continue to
utilize biomarkers to better understand how to interpret
and assess levels in bodily fluids and how they relate to
injury severity and outcome. We suggest that future
promising markers of brain tissue fate be compared with
S100B, as it appears to have the most utility of the TBI
markers studied to date, in order to determine how they
can add additional information concerning outcome and
assessment of injury.
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